Q-omics provides the consensus-scored RPH3AL profile across patient tissues and cancer cell-line models. RPH3AL expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPH3AL is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, RPH3AL RNA expression shows 18,531 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KICH, and ACC as cancer lineages where RPH3AL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPH3AL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPH3AL survival associations across molecular data types. RPH3AL RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPH3AL RNA expression–survival associations across cancer types. High RPH3AL expression shows unfavorable associations in UVM and LUSC, but favorable associations in BLCA, MESO, KIRC and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPH3AL RNA expression.
This table summarizes RPH3AL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RPH3AL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPH3AL shows lower tumor expression in KICH, HNSC, LUSC, BRCA and KIRC and higher tumor expression in STAD. The KICH box plot shows higher RPH3AL RNA expression in normal versus tumor tissue (log2 FC = −1.199, t-test p < 0.001).
This table shows molecular features associated with RPH3AL in patient tissues and cancer cell lines. In patient samples, RPH3AL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPH3AL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_NSCLC_LUAD.
